GEVA Key Stats
- FDA Designation for Synageva Candidate - Analyst Blog Zacks 5:20 PM
- Synageva's Sebelipase Alfa Receives Breakthrough Therapy Designation for Early O... May 20
- 3 Horrendous Health-Care Stocks This Week Fool May 18
- Synageva BioPharma™ Joins the International MPS Network in Support of MPS Awaren... May 15
- Nasdaq stocks posting largest percentage decreases AP May 14
- Nasdaq stocks posting largest percentage decreases May 13
- UPDATE: J.P. Morgan Downgrades Synageva BioPharma to Neutral on Challenges Ahead Benzinga May 10
- Synageva BioPharma Corp Enters Oversold Territory (GEVA) May 10
- Synageva downgraded to Neutral from Overweight at JPMorgan May 10
- A Peek Into The Market Before The Trading Starts Benzinga May 10
GEVA Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Synageva BioPharma is up 2.55% over the last year vs S&P 500 Total Return up 28.68%, Infinity Pharmaceuticals up 88.85%, and Imprimis Pharmaceuticals up 126.5%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for GEVA
Pro Report PDF for GEVA
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download GEVA Pro Report PDF
Pro Strategies Featuring GEVA
Did Synageva BioPharma make it into our Pro Portfolio Strategies?